SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/48C53746D84289BFB07B86EF4AF40A9E9BF845E9149E91FED0A49F08F7E5F1F42DE12CC9A29F83EF75652DF75A7BA0FB>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/48C53746D84289BFB07B86EF4AF40A9E9BF845E9149E91FED0A49F08F7E5F1F42DE12CC9A29F83EF75652DF75A7BA0FB
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/48C53746D84289BFB07B86EF4AF40A9E9BF845E9149E91FED0A49F08F7E5F1F42DE12CC9A29F83EF75652DF75A7BA0FB
http://www.w3.org/2000/01/rdf-schema#comment
"in p-stage I NSCLC patients those in the higher EphA2 expression and higher ephrin-A1 expression groups shared almost the same clinicopathological backgrounds which are generally considered to be better prognostic factors."
xsd:string
http://purl.uniprot.org/uniprot/#_04938413030D39AED23AB1E8485C7F8F6E4C79B4AB1C8EBB597B03E1BCC1224A41CD1B155890991621BB12BF2A2F8514
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/48C53746D84289BFB07B86EF4AF40A9E9BF845E9149E91FED0A49F08F7E5F1F42DE12CC9A29F83EF75652DF75A7BA0FB
http://purl.uniprot.org/uniprot/P20827
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/48C53746D84289BFB07B86EF4AF40A9E9BF845E9149E91FED0A49F08F7E5F1F42DE12CC9A29F83EF75652DF75A7BA0FB
http://purl.uniprot.org/uniprot/#_P20827-mappedCitation-22236865
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/48C53746D84289BFB07B86EF4AF40A9E9BF845E9149E91FED0A49F08F7E5F1F42DE12CC9A29F83EF75652DF75A7BA0FB